Physical findings in dengue infection [n/number observed (%)].

a<p>significantly less common in UF compared to DF and DHF, but no difference between DF and DHF.</p>b<p>significantly more common in DHF compared to DF and UF, and more common in DF compared to UF.</p

Clinical diagnosis of UF cases.

a<p>Statistically significant difference.</p

The prevalence (%) of clinical manifestation of dengue diseases from previous studies.

<p>ND = no data.</p>a<p>include both myalgia and arthralgia.</p

Symptoms of dengue infection [n (%)].

a<p>significantly more common in DHF compared to DF and UF, but no difference between UF and DF.</p>b<p>significantly less common in UF compared to DF and DHF, but no difference between DF and DHF.</p>c<p>significantly more common in DHF compared to DF and UF, and more common in DF compared to UF.</p

The prevalence of common symptoms in dengue infection by the day of illness.

<p>The prevalence of common symptoms in dengue infection by the day of illness.</p

Symptoms and disease severity from different dengue serotypes [n (%)].

<p>Symptoms and disease severity from different dengue serotypes [n (%)].</p

Occurrence of selected clinical manifestations [n/total] and their predictive value (%) for DHF among dengue infected cases.

<p>Occurrence of selected clinical manifestations [n/total] and their predictive value (%) for DHF among dengue infected cases.</p

The number of dengue infected patients who had prolonged symptom (for 3 or more days) [n (%)].

<p>NA = not applicable.</p>a<p>significantly more common in DHF compared to DF and UF, but no difference between DF and UF.</p>b<p>significantly less common in UF compared to DF and DHF, but no difference between DF and DHF.</p>c<p>significantly more common in UF compared to DF and DHF, but no difference between DF and DHF.</p>d<p>significantly less common in DF compared to UF and DHF, but no difference between UF and DHF.</p

Correlation between IgG and IgG subclass responses to PfRh4 proteins.

<p>Notes: Correlation coefficients are Spearman’s rho.*: p<0.0001. Bold: p<0.05. Others: not significant. IgG: total IgG. Antibodies measured by ELISA.</p

Expression of PfRh4 in clinical isolates and culture-adapted strains.

<p>(a) A representative example of a schizont from a clinical <i>P. falciparum</i> isolate with PfRh4 expression, as determined by immunofluorescence microscopy. Order of panels: phase, DAPI stain (labels nucleus), anti-Ron4-Alexa 488, anti-Rh4-Alexa-597, overlay. (b) Western blots showing expression of PfRh4 by <i>P. falciparum</i> isolates recently adapted to in vitro culture. Proteins were extracted from schizonts and the membrane was probed with anti-PfRh4 antibodies (upper panel) and anti-HSP70 antibodies (lower panel) as a loading control. The positions of molecular weight standards are indicated on the left. Isolates tested were 3D7, XIE (from PNG), Pf2004 (Ghana), Pf2006 (Ghana), HCS3 (Thailand) and a W2mef-PfRh4 knockout line (Rh4ko).</p